MedPath
FDA Approval

IBANDRONATE SODIUM

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
July 2, 2022
Labeling Type
Human Prescription Drug Label
Ibandronate(150 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited

676369519

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

IBANDRONATE SODIUM

Product Details

NDC Product Code
33342-150
Application Number
ANDA206887
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
July 2, 2022
Code: J12U072QL0Class: ACTIMQuantity: 150 mg in 1 1
HYPROMELLOSESInactive
Code: 3NXW29V3WOClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
POVIDONEInactive
Code: FZ989GH94EClass: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61UClass: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
TALCInactive
Code: 7SEV7J4R1UClass: IACT
POLYETHYLENE GLYCOLInactive
Code: 3WJQ0SDW1AClass: IACT
CROSPOVIDONEInactive
Code: 68401960MKClass: IACT
© Copyright 2025. All Rights Reserved by MedPath